Literature DB >> 2937274

Sclerosing cholangitis associated with hepatic arterial FUDR chemotherapy: radiographic-histologic correlation.

W J Shea, B E Demas, H I Goldberg, D C Hohn, L D Ferrell, R K Kerlan.   

Abstract

During a 2-year period, cholangiography was performed on 17 patients with clinical evidence of cholestasis who were receiving hepatic intraarterial floxuridine (IA-FUDR) infusions for treatment of metastatic colorectal adenocarcinoma. The development of cholestasis was associated with persistently elevated alkaline phosphatase, but serial CT examinations of the liver showed no progression of the tumor. All patients had cholangiographic abnormalities (by endoscopic retrograde cholangiopancreatography, percutaneous transhepatic cholangiography, or operative cholangiography) of the biliary ductal system similar to those in idiopathic sclerosing cholangitis. Certain features, however, appear specific to IA-FUDR-induced cholestasis. All patients studied had segmental involvement at the common hepatic duct bifurcation. The cystic duct and gallbladder were often involved, but the distal common bile duct was spared. Histologic features of periportal and periductal fibrosis were present in specimens obtained from percutaneous liver biopsy in three patients, cholecystectomy in four patients, and autopsy in two patients. When clinical signs of hepatic dysfunction occur in the absence of tumor progression, biliary sclerosis must be suspected.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2937274     DOI: 10.2214/ajr.146.4.717

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  14 in total

1.  Chemoembolization with drug-eluting beads complicated by intrahepatic biloma.

Authors:  Michael Naumann; Richard Bonsall; Ramona Gupta
Journal:  Semin Intervent Radiol       Date:  2011-06       Impact factor: 1.513

Review 2.  Haemodynamic events and localised parenchymal changes following transcatheter arterial chemoembolisation for hepatic malignancy: interpretation of imaging findings.

Authors:  J Chung; J-S Yu; J-J Chung; J H Kim; K W Kim
Journal:  Br J Radiol       Date:  2009-07-06       Impact factor: 3.039

3.  Regional and systemic chemotherapy for colorectal metastases to the liver.

Authors:  C M Balch; B Levin
Journal:  World J Surg       Date:  1987-08       Impact factor: 3.352

Review 4.  Primary sclerosing cholangitis.

Authors:  Y Ueno; N F LaRusso
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

5.  Sclerosing cholangitis with hepatic microvesicular steatosis in cystic fibrosis and chronic pancreatitis.

Authors:  I Benett; B Salh; N Y Haboubi; J M Braganza
Journal:  J Clin Pathol       Date:  1989-05       Impact factor: 3.411

6.  [Animal experiment studies of the toxicity of fluorodeoxyuridine (FUDR) and 5-fluorouracil (FU) within the scope of regional liver infusion chemotherapy].

Authors:  P Schlag; J Yi; P Friedl; W Hull; M Berger
Journal:  Langenbecks Arch Chir       Date:  1990

7.  Hilar biliary obstruction: malignant masquerades.

Authors:  Anne M Covey; George I Getrajdman
Journal:  Semin Intervent Radiol       Date:  2007-03       Impact factor: 1.513

8.  Chemotherapy-induced sclerosing cholangitis as a rare indication for resection: report of a case.

Authors:  Yutaro Kato; Kentaro Matsubara; Yoshinobu Akiyama; Hiroaki Hattori; Akira Hirata; Fumio Suzuki; Hitoshi Ohtaka; Ayu Kato; Yoshiaki Sugiura; Masaki Kitajima
Journal:  Surg Today       Date:  2009-09-27       Impact factor: 2.549

9.  A longitudinal study of histologic and immunohistologic changes in an experimental model of sclerosing cholangitis.

Authors:  P Bedossa; S Houry; J Bacci; E Martin; G Lemaigre; M Huguier
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

10.  Case report: Secondary sclerosing cholangitis induced by lapatinib and vinorelbine in a metastasis breast cancer patient.

Authors:  Zhuo Zhang; Ling Xu; Naishan Qin; Jixin Zhang; Qian Xiang; Qian Liu; Yuanjia Cheng; Yuge Bai; Qianxin Liu; Yinhua Liu; Xuening Duan; Yimin Cui
Journal:  Thorac Cancer       Date:  2021-05-06       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.